



Press Release

Louvain-la-Neuve, Belgium and Lalaye, France – March 16, 2016

## **BRACHYTHERAPY MARKET TO GROW BY 8% TO 2030, NEW VENDORS AND NEW PRODUCTS TO COME**

The global market for brachytherapy reached US\$ 705 million in 2015, of which the High-Dose Rate (HDR) and Low-Dose-Rate (LDR) segments accounted for just over 60%, the microspheres and electronic brachytherapy commanded the remaining 40%.

The global brachytherapy market in 2015, expressed in US dollars, has been affected by exchange rate fluctuations of the major currencies against the US dollar. The brachytherapy market size displayed an annual growth of 3% during the last two years to reach US\$ 705 million in 2015. Without this exchange rate influence, MEDraysintell estimates that the brachytherapy market would have reached about US\$ 800 million, thereby exhibiting an annual growth of more than 8%.

The brachytherapy market is expected to reach US\$ 2 billion in 2030, growing by 8% annually, mainly driven by the microspheres market as well as electronic brachytherapy, which is gaining significant interest worldwide as a user-friendly technology. The LDR (Low Dose Rate) brachytherapy seeds market is expected to grow substantially in new large markets such as China and India because of its reduced cost, together with a high therapeutic success rate.

The top ten companies control about 80% of the world brachytherapy market and more than 20 companies share the remaining 20%. Several new companies have penetrated the brachytherapy market in the last few years and a few others are expected to join the market in the coming years.

The global brachytherapy industry is evaluated in a new and updated MEDraysintell's report and directory, providing in a 340-page document a complete description of the radionuclides and devices used in brachytherapy, and a detailed profile of 62 companies and institutions active in this field around the world.

More information and table of contents is available at:

<http://medraysintell.com/Brachytherapy.html>

### **About MEDraysintell**

**Strategic intelligence for the radiation healthcare**

*Bringing value to Businesses and Investors!*

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy.

We offer the most comprehensive set of reports and directories, with over 1,800 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. [www.medraysintell.com](http://www.medraysintell.com)

### **Contact**

**Paul-Emmanuel Goethals, MBA**  
Louvain-la-Neuve, Belgium  
e-Mail: [peg@medraysintell.com](mailto:peg@medraysintell.com)  
Mobile: +32 491 080 968

**Richard Zimmermann, PhD**  
Lalaye, France  
e-Mail: [rz@medraysintell.com](mailto:rz@medraysintell.com)  
Mobile: +33 6 82 80 06 00